217 results on '"Savir-Baruch, Bital"'
Search Results
2. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)
3. Miscellaneous
4. Skeletal System
5. Genitourinary System
6. Pulmonary System
7. Radionuclide Therapy
8. Cardiovascular System
9. Endocrine System
10. Oncology and PET/CT
11. Central Nervous System
12. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
13. Prostate Cancer Imaging with 18F-Fluciclovine
14. Positivity Rate of [18F]Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Below 1 ng/mL
15. Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiothérapie Urologique Prostate Bed Contouring Guidelines for Post-Prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial
16. Beyond the AJR: PET/MRI Using 68Ga-RM2 Has Superior Performance to MRI Alone in the Localization of Lesions in Patients With Biochemical Failure After Prostate Cancer Treatment
17. 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE
18. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy
19. Part 1: Basics of Nuclear Medicine Flash Facts
20. Part 6: Nuclear Medicine – Radionuclide Therapies
21. Part 4: FDA-Approved PET/CT Tracers
22. Part 3: Clinical Nuclear Medicine – Whole-Body Scans
23. Part 5: Clinical Nuclear Medicine – Multi-use Radiopharmaceuticals-Based Flash Facts
24. Part 2: Clinical Nuclear Medicine – Head to Toe
25. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0
26. Imaging of Prostate Cancer Using Fluciclovine
27. Imaging of Prostate Cancer Using Fluciclovine
28. Computer assisted interpretation of Tc-99m mercaptoacetyltriglycine diuretic scintigraphy enhances resident performance
29. Impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials
30. Emerging Role of Fluciclovine and Other Next Generation PET Imaging Agents in Prostate Cancer Management
31. Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer
32. ACR–ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer
33. Metastatic Male Breast Cancer With Increased Uptake on 18F-Fluciclovine PET/CT Scan
34. RadTool Nuclear Medicine Flash Facts
35. Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT
36. Effect of hormonal therapy on 18F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigen
37. 177Lu-PSMA Therapy
38. ACR–ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders
39. Reproducibility and Reliability of Anti-3-[18F]FACBC Uptake Measurements in Background Structures and Malignant Lesions on Follow-Up PET-CT in Prostate Carcinoma: an Exploratory Analysis
40. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy
41. Part 1: Basics of Nuclear Medicine Flash Facts
42. Part 2: Clinical Nuclear Medicine – Head to Toe
43. Part 5: Clinical Nuclear Medicine – Multi-use Radiopharmaceuticals-Based Flash Facts
44. Part 6: Nuclear Medicine – Radionuclide Therapies
45. Part 3: Clinical Nuclear Medicine – Whole-Body Scans
46. Part 4: FDA-Approved PET/CT Tracers
47. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
48. Positivity Rate of [18F]Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Below 1 ng/mL
49. PET Imaging for Prostate Cancer
50. 177Lu-PSMA Therapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.